Engineered combination broadly neutralizing antibodies in HIV research are showing clinically relevant durability signals. A systematic review of 34 clinical trials found engineered antibody combinations extend circulation and delay HIV-1 rebound by up to 33 weeks, suggesting progress toward more durable humoral control. In parallel, a laboratory-focused study described a re-engineered monoclonal antibody VYD222 (pemivibart) maintaining broad and potent neutralization against SARS-CoV-2 variants. Structural work explains how engineered mutations preserve activity across evolving spike changes and constrain escape. While these programs span different pathogens, both developments highlight the same engineering theme: using structure-informed redesigns (or antibody combinations) to extend functional durability and reduce escape risk.